Genmab A/S · OMXCOP:GMAB
Genmab A/S — FY2009 Earnings Presentation
8 slides from Genmab A/S's earnings presentation, March 2010
Slide 1: Financial Summary
Financial Summary For 12 months ended December 31, 2009
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, inclu
Slide 3: Financial Summary – Key Data
Annual Report 2009 Financial Summary – Key Data 12 Months ended December 31, 2009 2009 2008 2009 2008 DKK millions USD millions * Revenue 586 692 113 133 Net Loss (1,011) (965) (195) (186) R&D employees 269 505 All other employees 40 50 Employees at end of period 309 555 DKK millions USD millions *
Slide 4: Financial Summary – Income Statement
Annual Report 2009 Financial Summary – Income Statement 12 Months ended December 31, 2009 2009 2008 2009 2008 DKK millions USD millions * Revenue 586 692 113 133 R&D Costs (935) (1,271) (180) (245) G&A Expenses (149) (143) (29) (28) Operating Expenses (1,084) (1,414) (209) (273) Operating Loss (498)
Slide 5: Comparison to last guidance
Annual Report 2009 Comparison to last guidance 2009 Actual result Continuing Discontinued Previous Total Operations Operations Guidance DKK DKK DKK Millions DKK Millions Millions Millions Revenue 586 42 628 640 Operating Expenses (1,030) (239) (1,269) (1,300) Reorganization Charge (54) (47) (101) (8
Slide 6: Highlights
Annual Report 2009 Highlights Ofatumumab FDA accelerated approval for CLL refractory to fludarabine & alemtuzumab Submitted marketing authorization application to EMEA for CLL CHMP positive opinion for CLL refractory to fludarabine & alemtuzumab Published results from four ofatumumab studies 17 stud
Slide 7: Guidance 2010
Guidance 2010 Note Arzerra Royalties are not Guidance 2010 included in this guidance DKK Millions USD Millions * Revenue 350 - 450 67 - 87 Operating Expenses (950) - (1,050) (183) - (202) Operating Loss from Continuing Ops. (550) - (650) (106) - (125) Discontinued Operations (50) (10) Facility Sale
Slide 8: Slide 8